"Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Descriptor ID |
D018358
|
| MeSH Number(s) |
C04.557.465.625.650 C04.557.580.625.650
|
| Concept/Terms |
Neuroendocrine Tumors- Neuroendocrine Tumors
- Neuroendocrine Tumor
- Tumor, Neuroendocrine
- Tumors, Neuroendocrine
|
Below are MeSH descriptors whose meaning is more general than "Neuroendocrine Tumors".
Below are MeSH descriptors whose meaning is more specific than "Neuroendocrine Tumors".
This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in this website by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 5 | 0 | 5 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 4 | 0 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.
-
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study. Clin Cancer Res. 2024 Dec 16; 30(24):5559-5567.
-
PIT-1/SF-1 co-expression in pituitary neuroendocrine tumors (PitNETs) with comprehensive review of the literature: How should we best characterize these neoplasms? Ann Diagn Pathol. 2025 Feb; 74:152398.
-
Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors. Curr Oncol Rep. 2024 Nov; 26(11):1530-1542.
-
Spectra of well-differentiated neuroendocrine lesions in the extrahepatic biliary system: a case series. Histopathology. 2025 Jan; 86(2):285-293.
-
Development of an artificial intelligence-based model to predict early recurrence of neuroendocrine liver metastasis after resection. J Gastrointest Surg. 2024 Nov; 28(11):1828-1837.
-
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Res. 2024 Jul 22; 52(13):7740-7760.
-
Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prev Res (Phila). 2024 Jul 02; 17(7):335-342.
-
Introduction to Guest Section on Neuroendocrine Tumors. J Comput Assist Tomogr. 2024 Jul-Aug 01; 48(4):509.
-
Thoracic solitary fibrous tumors with small cell features: A clinicopathological and immunohistochemical analysis of 5 cases. Ann Diagn Pathol. 2024 Dec; 73:152353.
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 06 29; 403(10446):2807-2817.